BEDFORD, Mass., Nov. 5, 2012 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that its suite of gynecologic surgical products will be on display at the 41st AAGL Global Congress on Minimally Invasive Gynecology, November 5-9, 2012, in Las Vegas, NV. The American Association of Gynecologic Laparoscopists (AAGL) is the leading association promoting minimally invasive gynecologic surgery among surgeons worldwide.
This year, Hologic will debut the MyoSure XL fibroid removal device an addition to the MyoSure product line. Both the MyoSure tissue removal system and MyoSure XL fibroid removal device provide incisionless treatment options for relieving abnormal uterine bleeding (AUB) symptoms and infertility caused by endometrial polyps and submucosal fibroids. With the MyoSure XL device a physician is able to hysteroscopically remove a 5cm fibroid in less than 15 minutes.
"We are pleased to share real-world and practical insights that deepen the understanding of the safety and efficacy of our MyoSure product family as well as our NovaSure endometrial ablation system at AAGL this year," said Shacey Petrovic, Vice President and General Manager of Hologic's GYN Surgical Products Division. "These products provide options to effectively treat polyps, fibroids and abnormal uterine bleeding without requiring major surgery and underscore our unwavering commitment to advancing women's health."
Abnormal uterine bleeding (AUB) is bleeding that is not part of a woman's normal menstrual cycle. Today, an estimated 20 percent of all women experience AUB. The majority of women are not aware that AUB is a real medical condition that can range from extremely heavy bleeding to irregular periods (outside the usual 21 to 28-day monthly cycle). Because women are reluctant to talk about changes in their periods, they often suffer in silence unnecessarily and forego treatment for years. Hologic's MyoSure and NovaSure procedures are minimally invasive and are designed to treat women with abnormal uterine bleeding.
In addition to the MyoSure product line, Hologic will display the full range of products in its gynecologic surgical suite.
- NovaSure Endometrial Ablation System: Since 2001, more than 1.5 million women have been treated with the NovaSure procedure to reduce or eliminate heavy menstrual bleeding, without hormones or an invasive hysterectomy. Earlier this year, Hologic launched a patient-centered campaign changethecycle.com using best-selling author Vicki Iovine ("The Girlfriend's Guide to Pregnancy") to connect former patients with future patients to answer questions about heavy periods and NovaSure.
- Aquilex Fluid Control System: The Aquilex fluid control system was developed to simplify hysteroscopic procedures such as the MyoSure procedure. This high-performance system is designed to minimize the risk of inaccurate deficit readings and maintains constant uterine cavity distention throughout the MyoSure procedure.
- Tower-free Hysteroscopy System (THS): The THS is designed to meet the diverse diagnostic and treatment needs of the gynecologist's office. This versatile platform is compatible with Hologic's full range of gynecologic solutions, including planning for NovaSure and MyoSure procedures.
For more information about Hologic's gynecologic surgical products, presentations and sessions at AAGL, please visit booth 413.
About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products. The Company operates four core business units focused on breast health, diagnostics, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information, visit www.hologic.com.
Forward-Looking Statement Disclaimer
This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of the NovaSure, MyoSure, THS and Aquilex systems. There can be no assurance the systems will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of these systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic filings with the Securities and Exchange Commission.
Hologic, Aquilex, MyoSure, NovaSure and THS are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
SOURCE Hologic, Inc.